These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope. Kelley VE; Gaulton GN; Strom TB J Immunol; 1987 May; 138(9):2771-5. PubMed ID: 3106488 [TBL] [Abstract][Full Text] [Related]
3. Cross-linking of Lyt-2 (CD8) to the T cell antigen receptor optimally activates T lymphocytes. Boyce NW; Eichmann K Transplant Proc; 1989 Feb; 21(1 Pt 1):133-7. PubMed ID: 2495596 [No Abstract] [Full Text] [Related]
4. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
5. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. Hirsch R; Eckhaus M; Auchincloss H; Sachs DH; Bluestone JA J Immunol; 1988 Jun; 140(11):3766-72. PubMed ID: 3286764 [TBL] [Abstract][Full Text] [Related]
8. Activation requirements of cloned inducer T cells. I. Differential inhibition by anti-L3T4 or anti-I-A is determined by the accessory cell population. DeKruyff R; Clayberger C; Cantor H; Dorf ME J Immunol; 1985 Oct; 135(4):2243-8. PubMed ID: 3897372 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. Titus RG; Ceredig R; Cerottini JC; Louis JA J Immunol; 1985 Sep; 135(3):2108-14. PubMed ID: 3926895 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppression with an anti-IL-2 receptor monoclonal antibody in a baboon renal allograft model. Hayes JM; Spencer W; Valenzuela R; Caulfield M; Novick AC Transplant Proc; 1989 Feb; 21(1 Pt 1):1006-9. PubMed ID: 2650061 [No Abstract] [Full Text] [Related]
11. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts. Madsen JC; Peugh WN; Wood KJ; Morris PJ Transplantation; 1987 Dec; 44(6):849-52. PubMed ID: 3321596 [No Abstract] [Full Text] [Related]
17. Basis for differing biological immunosuppressive potencies of monoclonal and polyclonal T cell antibodies. Sherburne CG; Condie RM; Onyekaba CO Transplant Proc; 1989 Feb; 21(1 Pt 1):1036-9. PubMed ID: 2523113 [No Abstract] [Full Text] [Related]
18. Activation requirements for normal T cells: accessory cell-dependent and -independent stimulation by anti-receptor antibodies. Bekoff M; Kubo R; Grey HM J Immunol; 1986 Sep; 137(5):1411-9. PubMed ID: 3489033 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to idarubicin: studies in the mouse heart graft model. Mottram PL; Pietersz GA; Purcell LJ; Clunie GJ; McKenzie IF Transplant Proc; 1990 Oct; 22(5):2111-2. PubMed ID: 2120812 [No Abstract] [Full Text] [Related]
20. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]